|
1
|
Ataya KM, McKanna JA, Weintraub AM, Clark
MR and LeMaire WJ: A luteinizing hormone-relasing hormone agnist
for the prevention of chemotherapy-induced ovarian fllicular loss
in rats. Cancer Res. 45:3651–3656. 1985.PubMed/NCBI
|
|
2
|
Blumenfeld Z and Eckman A: Preservation of
fertility and ovarian function and minimization of
chemotherapy-induced gonadotoxicity in young women by GnRH-a. J
Nail Cancer Inst Monogr. 34:40–43. 2005. View Article : Google Scholar
|
|
3
|
Badawy A, Elnashar A, El-Ashry M and
Shahat M: Gonadotropin-releasing hormone agonists for prevention of
chemotherapy-induced ovarian damage: Prospective randomized study.
Fertil Steril. 91:694–697. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Demeestere I, Brice P, Peccatori FA,
Kentos A, Dupuis J, Zachee P, Casasnovas O, Van Den Neste E,
Dechene J, De Maertelaer V, et al: No evidence for the benefit of
gonadotropin-releasing hormone agonist in preserving ovarian
function and fertility in lymphoma survivors treated with
chemotherapy: Final long-term report of a prospective randomized
trial. J Clin Oncol. 34:2568–2574. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Higgins JPT and Green S: Cochrane Handbook
for Systematic Reviews of Interventions. John Wiley & Sons.
(Ltd., Chichester). 2008. View Article : Google Scholar
|
|
6
|
Elgindy EA, El-Haieg DO, Khorshid OM,
Ismail EI, Abdelgawad M, Sallam HN and Abou-Setta AM: Gonadatrophin
suppression to prevent chemotherapy-induced ovarian damage: A
randomized controlled trial. Obstet Gynecol. 121:78–86. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Gerber B, von Minckwitz G, Stehle H,
Reimer T, Felberbaum R, Maass N, Fischer D, Sommer HL, Conrad B,
Ortmann O, et al: Effect of luteinizing hormone-releasing hormone
agonist on ovarian function after modern adjuvant breast cancer
chemotherapy: the GBG 37 ZORO study. J Clin Oncol. 29:2334–2341.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Giuseppe L, Attilio G, Edoardo DN,
Loredana G, Cristina L and Vincenzo L: Ovarian function after
cancer treatment in young women affected by Hodgkin disease (HD).
Hematology. 12:141–147. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Karimi-Zarchi M, Forat-Yazdi M,
Vafaeenasab MR, Nakhaie-Moghadam M, Miratashi-Yazdi A, Teimoori S
and Dehghani-Tafti A: Evaluation of the effect of GnRH agonist on
menstrual reverse in breast cancer cases treated with
cyclophosphamide. Eur J Gynaecol Oncol. 35:59–61. 2014.PubMed/NCBI
|
|
10
|
Lambertini M, Boni L, Michelotti A,
Gamucci T, Scotto T, Gori S, Giordano M, Garrone O, Levaggi A,
Poggio F, et al: Ovarian suppression with triptorelin during
adjuvant breast cancer chemotherapy and long-term ovarian function,
pregnancies, and disease-free survival: A randomized clinical
trial. JAMA. 314:2632–2640. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Leonard RCF, Adamson DJA, Bertelli G,
Mansi J, Yellowlees A, Dunlop J, Thomas GA and Coleman RE; Anglo
Celtic Collaborative Oncology Group and National Cancer Research
Institute Trialists, : GnRH agonist for protection against ovarian
toxicity during chemotherapy for early breast cancer: The Anglo
Celtic Group OPTION trial. Ann Oncol. 28:1811–1816. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Moore HC, Unger JM, Phillips KA, Boyle F,
Hitre E, Porter D, Francis PA, Goldstein LJ, Gomez HL, Vallejos CS,
et al: Goserelin for ovarian protection during breast-cancer
adjuvant chemotherapy. N Engl J Med. 372:923–932. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Munster PN, Moore AP, Ismail-Khan R, Cox
CE, Lacevic M, Gross-King M, Xu P, Carter WB and Minton SE:
Randomized trial using gonadotropin-releasing hormone agonist
triptorelin for the preservation of ovarian function during
(neo)adjuvant chemotherapy for breast cancer. J Clin Oncol.
30:533–538. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Song G, Gao H and Yuan Z: Effect of
leuprolide acetate on ovarian function after
cyclophosphamide-doxorubicin-based chemotherapy in premenopausal
patients with breast cancer: Results from a phase II randomized
trial. Med Oncol. 30:6672013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sverrisdottir A, Nystedt M, Johansson H
and Fornander T: Adjuvant goserelin and ovarian preservation in
chemotherapy treated patients with early breast cancer: Results
from a randomized trial. Breast Cancer Res Treat. 117:561–567.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
LHRH-agonists in Early Breast Cancer
Overview Group, ; Cuzick J, Ambroisine L, Davidson N, Jakesz R,
Kaufmann M, Regan M and Sainsbury R: Use of
luteinising-hormone-releasing hormone agonists as adjuvant
treatment in premenopausal patients with hormone-receptor-positive
breast cancer: A meta-analysis of individual patient data from
randomised adjuvant trials. Lancet. 369:1711–1723. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zheng W, Magid MS, Kramer EE and Chen YT:
Follicle-stimulating hormone receptor is expressed in human ovarian
surface epithelium and fallopian tube. Am J Pathol. 148:47–53.
1996.PubMed/NCBI
|
|
18
|
Periti P, Mazzei T and Mini E: Clinical
pharmacokinetics of depot leuprorelin. Clin Pharmacokinet.
41:485–504. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Badaru A, Wilson DM, Bachrach LK, Fechner
P, Gandrud LM, Durham E, Wintergerst K, Chi C, Klein KO and Neely
EK: Sequential comparisons of one-month and three-month depot
leuprolide regimens in central precocious puberty. J Clin
Endocrinol Metab. 91:1862–1867. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kitajima Y, Endo T, Nagasawa K, Manase K,
Honnma H, Baba T, Hayashi T, Chiba H, Sawada N and Saito T:
Hyperstimulation and a gonadotropin releasing hormone agonist
modulate ovarian vascular permeability by altering expression of
the tight junction protein claudin-5. Endocrinology. 147:694–699.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Reinsch RC, Murphy AA, Morales AJ and Yen
SS: The effects of RU 486 and leuprolide acetate on uterine artery
blood flow in the fibroid uterus: A prospective, randomized study.
Am J Obstet Gynecol. 170:1623–1627. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ng EH, Tang OS, Chan CC and Ho PC: Ovarian
stromal blood flow in the prediction of ovarian response during in
vitro fertilization treatment. Hum Reprod. 20:3147–3151. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Jarvela IY, Sladkevicius P, Kelly S, Ojha
K, Campbell S and Nargund G: Effect of pituitary down-regulation on
the ovary before in vitro fertilization as measured using
threedimensional power Doppler ultrasound. Fertil Steril.
79:1129–1135. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Choi JH, Gilks CB, Auersperg N and Leung
PC: Immunolocalization of gonadotropin-releasing hormone(GnRH)-I,
GnRH-II and type I GnRH receptor during follicular development in
the human ovary. J Clin Endocrinol Metab. 91:4562–4570. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Imai A, Sugiyama M, Furui T, Tamaya T and
Ohno T: Direct protection by a gonadotropin-releasing hormone
analog from doxorubicin-induced granulosa cell damage. Gynecol
Obstet Invest. 63:102–106. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Morita Y and Tilly JL: Oocyte apoptosis:
Like sand through an hourglass. Dev Biol. 213:1–17. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Reynolds T: Cell death genes may hold
clues to preserving fertility after Chemotherapy. Natl Cancer Inst.
91:664–666. 1999. View Article : Google Scholar
|
|
28
|
Morita Y, Perez GI, Paris F, Miranda SR,
Ehleiter D, Haimovitz-Friedman A, Fuks Z, Xie Z, Reed JC, Schuchman
EH, et al: Oocyte apoptosis is suppressed by disruption of the acid
sphingomyelinase gene or by sphingosine-1-phosphate therapy. Nat
Med. 6:1109–1114. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
29
|
Johnson J, Canning J, Kaneko T, Pru JK and
Tilly JL: Germline stem cells and follicular renewal in the
postnatal mammalian ovary. Nature. 428:145–150. 2004. View Article : Google Scholar : PubMed/NCBI
|
